T&R Biofab Selected for Pan-Government Full-Cycle Medical Device R&D Project

[Asia Economy Reporter Park Hyungsoo] 3D bioprinting company T&R Biofab announced on the 11th that it has been selected for the project "Development of medical materials and devices with enhanced functionality through heterogenous material complexation" under the Pan-Government Full-Cycle Medical Device R&D Program.

The Pan-Government Full-Cycle Medical Device R&D Program is a large-scale medical device development project in South Korea jointly promoted by four ministries: the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety. This program supports the entire cycle of medical device development from technology development to clinical trials and regulatory approval.

The lead institution selects project-performing companies by focusing on their capabilities to lead the 4th Industrial Revolution and future medical environments. It provides focused support for the development of customized materials and productization of medical devices.

As T&R Biofab has been selected for the government project, it will receive up to 3.75 billion KRW in research funding from the government over a total of 3 years and 9 months until December 2025. Through this government project, the company will carry out ▲development of customized heterogenous materials and processes ▲development of next-generation nerve regeneration implant medical devices ▲medical device productization and regulatory approval. Seoul Asan Medical Center will participate as a joint research institution.

The "nerve regeneration implant" that T&R Biofab is promoting for development is an in vivo implant in the form of a guidance conduit inserted into the severed nerve area to assist rapid growth, regeneration, and recovery of damaged nerves.

Dr. Kim Inho of T&R Biofab, the project leader, said, "Based on globally recognized 3D bioprinting technology, we will develop a successful customized nerve regeneration implant." He added, "We expect to effectively target the domestic and international nerve regeneration and heterogenous material medical device markets through the launch of innovative products with global competitiveness."

This content was produced with the assistance of AI translation services.